Asterand Receives Contract Extension From NCI (6575R)

TIDMATD

RNS Number : 6575R

Asterand PLC

08 November 2011

For Immediate Release 8 November 2011

Asterand plc

Asterand Receives Contract Extension From NCI

Asterand plc ("Asterand" or the "Company" - LSE: ATD) announces today that, further to the announcement on 23 September 2011, it has received notification from the National Cancer Institute ("NCI") that it will grant the Company a no cost contract extension to 30 September 2014 for The Cancer Genome Atlas contract ("TCGA"). This extension will allow Asterand to realise unexpended funds for the initial $5.4m contract beyond the original expiration date of 23 February 2012.

Contacts:

 
 Asterand plc 
 Jack Davis, Chairman and Interim Chief   Tel: + 44 (0) 1763 211 600 / + 
  Executive Officer                        1 (313) 263-0960 
 Alan Fishman, Interim Chief Financial    As above 
  Officer 
 
 Buchanan Communications 
 Lisa Baderoon / Mark Court / Isabel      Tel: +44 (0) 20 7466 5000 
  Podda 
 
 Daniel Stewart & Company plc 
 Antony Legge                             Tel: +44 (0) 20 7776 6550 
 Martin Lampshire

About Asterand

Asterand plc is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate target discovery and compound validation and enable pharmaceutical and biotechnology companies to take safer and more effective drugs into the market. For more information about Asterand, go to www.asterand.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCZMMGMZNRGMZZ

Bioseek (LSE:ATD)
過去株価チャート
から 5 2024 まで 6 2024